Navigation Links
Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech, 2013 Edition
Date:4/25/2013

DUBLIN, April 25, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the "Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech, 3rd Edition" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter preclinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech provides the reader with the following key benefits:

- In-depth understanding of preclinical stage deal trends since 2007
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of preclinical stage agreements with numerous real life case studies
- Detailed access to actual preclinical stage deals entered into by the leading fifty big pharma and big biotech companies
- Insight into the terms included in a preclinical stage agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech includes

- Trends in preclinical stage dealmaking in the biopharma industry since 2007
- Analysis of preclinical stage deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life preclinical stage deals
- Access to over 2,200 preclinical stage deals
- The leading preclinical stage deals by value since 2007
- Most active preclinical stage dealmakers since 2007
- The leading preclinical stage partnering resources

In Preclinical Stage Partnering Terms and Agreements in Pharm and Biotech, the available contracts are listed by:

- Company A-Z
- Headline value
- Stage of development at signing
- Deal type
- Specific therapy target

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Why do companies partner preclinical stage compounds?

Chapter 3 - Preclinical stage deal strategies and structure

Chapter 4 - Preclinical stage partnering payment strategies

Chapter 5 - Trends in preclinical stage deal making

Chapter 6 - Average payment terms for preclinical stage partnering

Chapter 7 - Leading preclinical stage deals

Chapter 8 - Big pharma and big biotech preclinical stage partnering deals

Chapter 9 - Preclinical stage partnering contracts directory

Chapter 10 - Preclinical stage dealmaking directory

For more information visit Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech, 3rd Edition

Research and Markets
Laura Wood , Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
3. MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models
4. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
5. Preclinical data shows 100 percent prevention and treatment of influenza with engineered human antibody
6. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
7. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
8. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
9. RPCI-Led Study: FAK Inhibitor Proves Effective Against Brain Tumors in Preclinical Studies
10. PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
11. Translating Preclinical Pharmacology to Clinical Activity with Myriad RBM’s Inflammation MAP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016 On Monday, ... call to industry to share solutions for the Biometric ... U.S. Customs and Border Protection (CBP), explains that CBP ... are departing the United States , ... and to defeat imposters. Logo - ...
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
Breaking Biology News(10 mins):